C COLLEGIUM PHARMACEUTICAL INC
| Market Cap | $1.03B |
| P/E Ratio | 18.68 |
| Forward P/E | 5.06 |
| Dividend Yield | — |
| Beta | 0.77 |
| 52W Range | $24.67 - $49.84 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Third Avenue Management Third Avenue Management | 1.71% | $9.42M | 203,401 | — |
Insider Trading
| Insider Name of the company insider who made the trade 10 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Dieter DavidEVP & General Counsel | Sale | 13,976 | $34.92 | $488.10K | 18 Mar 2026 | 18 Mar 2026 |
| Dieter DavidEVP & General Counsel | Sale | 6,224 | $36.65 | $228.11K | 09 Mar 2026 | 09 Mar 2026 |
| Dreyer ScottEVP & Chief Commercial Officer | Sale | 46,417 | $40.36 | $1.87M | 03 Mar 2026 | 05 Mar 2026 |
| Dreyer ScottEVP & Chief Commercial Officer | Sale | 3,559 | $40.99 | $145.88K | 03 Mar 2026 | 05 Mar 2026 |
| Dreyer ScottEVP & Chief Commercial Officer | Sale | 11,125 | $47.89 | $532.77K | 08 Dec 2025 | 10 Dec 2025 |
| Dreyer ScottEVP & Chief Commercial Officer | Sale | 6,475 | $48.66 | $315.08K | 08 Dec 2025 | 10 Dec 2025 |
| Balice-Gordon Rita J. | Sale | 3,650 | $47.03 | $171.67K | 05 Dec 2025 | 09 Dec 2025 |
| Fallon John A. | Sale | 34,853 | $47.21 | $1.65M | 12 Nov 2025 | 14 Nov 2025 |
| Tupper ColleenEVP & Chief Financial Officer | Sale | 4,858 | $41.28 | $200.52K | 06 Nov 2025 | 07 Nov 2025 |
| Tupper ColleenEVP & Chief Financial Officer | Sale | 25,142 | $40.38 | $1.02M | 06 Nov 2025 | 07 Nov 2025 |
Frequently Asked Questions
What is COLL stock price today?
COLLEGIUM PHARMACEUTICAL INC (COLL) is currently trading at $32.31. The stock has a 52-week range of $24.67 to $49.84 and a market capitalization of $1.03B.
Is COLL a good stock to buy in 2026?
COLLEGIUM PHARMACEUTICAL INC has a P/E ratio of 18.7 (forward P/E: 5.1), a dividend yield of none, and 1-year performance of +11.3%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling COLL stock?
There have been 10 insider transactions for COLL in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has COLL stock performed over the past year?
COLLEGIUM PHARMACEUTICAL INC (COLL) has returned +11.3% over the past 12 months. The stock traded between $24.67 and $49.84 during this period, and is currently at $32.31.
Which hedge funds own COLL (COLLEGIUM PHARMACEUTICAL INC)?
1 tracked hedge funds currently hold COLL in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is COLL's market cap and valuation?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a market capitalization of $1.03B. The trailing P/E ratio is 18.7 and forward P/E is 5.1. The stock is classified in the Healthcare sector.
What is COLL's revenue and profitability?
COLLEGIUM PHARMACEUTICAL INC reported revenue of $780.57M with net income of $62.87M and a profit margin of 0.08%. The stock has a beta of 0.77.
What sector is COLL in and who are its biggest institutional holders?
COLLEGIUM PHARMACEUTICAL INC (COLL) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.